Form 8-K - Current report:
SEC Accession No. 0001641172-25-017283
Filing Date
2025-07-01
Accepted
2025-07-01 08:38:21
Documents
15
Period of Report
2025-06-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8k.htm   iXBRL 8-K 63196
2 EX-99.1 ex99-1.htm EX-99.1 14511
3 GRAPHIC ex99-1_001.jpg GRAPHIC 3504
  Complete submission text file 0001641172-25-017283.txt   256381

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE indp-20250630.xsd EX-101.SCH 3020
5 XBRL LABEL FILE indp-20250630_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE indp-20250630_pre.xml EX-101.PRE 22362
18 EXTRACTED XBRL INSTANCE DOCUMENT form8k_htm.xml XML 3619
Mailing Address 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY 10019
Business Address 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY 10019 (646) 427-2727
Indaptus Therapeutics, Inc. (Filer) CIK: 0001857044 (see all company filings)

EIN.: 863158720 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40652 | Film No.: 251094254
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)